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Protein-protein interactions (PPIs) are ubiquitous in essential 
biological processes such as cell proliferation and differentiation, 
host-pathogen interactions, and signal transduction pathways [1]. 
Pioneering advances in the field of  interactomics have uncovered 
new net-works of  protein interactions within cells, with esti-mates 
for the size of  the interactome ranging up to 650,000 PPIs [2]. 
However, targeting PPIs has histori-cally been considered to be 
a particularly challenging task due to their typically large size 
(>1,500 Å) and amorphous nature that lack well-defined crevices 
for recognition by small molecules. Not surprisingly, the pharma-
ceutical landscape over the last century has been dominated by 
programs for small molecule in-hibitors of  enzymes (particularly 
kinases), G-protein-coupled receptors, protein transporters and 
ion chan-nels that account for the majority of  known drugs.
Over the past two decades, however, revolutionary studies have 
established the notion of  so-called “hot-spots” within protein-
protein interfaces, which are small subsets of  residues that are 
responsible for most of  the binding affinity of  the protein to 
natural part-ners or synthetic small molecules [3]. Furthermore, 
scientists have gained greater appreciation into the plas-ticity of  
protein surfaces, such as the realization that protein-protein inter-
faces are dynamic and allow the formation of  transient binding 
pockets that may not be observable in the static structure of  the 
apo-protein or protein-protein complex. Protein-protein interfac-
es are exceedingly diverse, and, unfortunately, have not evolved 
for optimal interactions with small molecules. A computational 
study has suggested that the drug-gable sites within PPI interfaces 
typically comprise a cluster of  binding hotspots characterized by 
concave topology combined with a pattern of  hydrophobic and 
polar functionality [4]. Thus, the development of  PPI inhibitors 
has largely focused upon relatively large, rig-id and hydrophobic 
molecules that could interact more effectively with the bind-
ing pocket of  the protein-protein interface [5]. Indeed, the fru-
gal success rate of  early PPI inhibitor discovery programs may 
have stemmed from the bias for “drug-like” molecules in high-
throughput screening libraries. Most PPI inhibi-tors reported to 
date do not adhere to Lipinski’s rule of  five. A recent statistical 
analysis of  39 PPI inhibi-tors suggested a “rule of  four” frame-
work for small molecule PPI inhibitors where molecular weight > 
400, ALogP > 4, number of  rings > 4 and number of  hydrogen 
bond acceptors > 4 [6]. Although pep-tide or antibody biologics 
show strong efficacy against PPIs in isolated systems, issues with 
oral bioavailability, cell permeability and metabolic stability tend 
to limit their further development as potential PPI-modulating 
drugs.
An overarching goal in PPI inhibitor discovery has therefore been 
to expand the arsenal of  available chemical scaffolds, such as 
through biology-orientated or diversity-orientated approaches, to 
generate mol-ecules capable of  accessing larger regions of  chemi-
cal space available within the binding interfaces of  PPIs. Two 
small molecule PPI inhibitors, navitoclax and oba-toclax, function 
by antagonizing the Bcl-2 family of  proteins and are currently in 
Phase II clinical trials as anti-cancer agents. Our view is that two 
special classes of  compounds, natural products and metal com-
plexes, may represent the next frontier in the development of  PPI 
inhibitors for the treatment of  human diseases. Natural products 
represent a privileged source of  bioactive substructures that have 
been evolutionarily selected for optimal interactions with bio-
molecules. Furthermore, natural products offer a cornucopia of  
structural motifs, many of  which would fail simple drug-likeness 
screens, for sampling the diverse archi-tectures of  protein-protein 
interfaces. As an example, paclitaxel (Taxol), a diterpenoid iso-
lated from the bark of  the Pacific yew tree and its semisynthetic 
deriva-tive docetaxel (Taxotere) have been found to bind to and 
stabilize the β-subunit of  the tubulin heterodimer, thereby inter-
fering with the normal breakdown of  mi-crotubules during cell 
division. Our group has recently utilised high-throughput virtual 
screening to identify natural product-like inhibitors of  the TNF-α 
homo-trimer interaction[7].
Cytotoxic metal complexes, best exemplified by cispl-atin and its 
analogues, typically target DNA or other biomolecules through 
covalent, non-specific interac-tions to exert their anti-neoplas-
tic effects. Due to the adverse side effects associated with such 
“shotgun” metal complexes, however, there has been a recent 
up-surge in interest in the development of  kinetically-inert met-
al complexes as molecularly-targeted agents against enzymes or 
PPIs[8,9]. Transition metals possess vari-able oxidation states and 
molecular geometries (e.g. octahedral, square-planar) that enable 
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the design of  in-tricate coordination sphere architectures. The 
ability to arrange organic ligands in a precise three-dimensional 
arrangement around the metal center can be harnessed to gener-
ate unique scaffolds for recognizing the bind-ing sites of  PPIs. 
However, few metal-based PPI mod-ulators have yet been discov-
ered in the literature.
Despite promising initial studies, the realm of  small molecule 
modulators of  PPIs can be still considered as an immature dis-
cipline. Besides exploring new classes of  molecules, future stud-
ies could be directed towards the further elucidation of  protein-
protein interfaces and the mechanisms of  inhibition exhibited by 
small molecules. For example, α-helix, β-strand and mixed α/β 
PPI domains have all been successfully targeted by small mol-
ecules, and it might be envisioned that par-ticular 3D topological 
scaffolds would necessitate dis-tinct structural requirements in the 
ligands. In terms of  mechanism, molecules may be designed to 
inhibit PPIs via orthosteric or allosteric inhibition, where ligands 
bind at or away from the protein-protein interface, respectively. 
Improved structural biological under-standing and computational 
algorithms could also en-hance the utility of  molecular docking 
techniques for high-throughput virtual screening or structure-
based rational design of  PPI modulators [10]. Challenges not-
withstanding, we believe that this exciting field will continue to 
thrive and mature in the years to come.
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